Literature DB >> 16678288

The effect of statin on the aortic gene expression profiling.

Shu-Lin Liu1, Yi-Heng Li, Guey-Yueh Shi, Meei-Jyh Jiang, Jing-Hong Chang, Hua-Lin Wu.   

Abstract

BACKGROUND: Beyond lipid lowering, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) has been found to have anti-inflammatory and anti-thrombotic effects. However, the genetic expression pattern changes in atherosclerotic lesions produced by statin are rarely studied.
METHODS: Cholesterol-fed apolipoprotein (Apo) E-deficient mice were examined for the treatment effect of statin on aortic gene expression. ApoE-deficient mice were fed with a hypercholesterolemic diet started at 8 weeks of age for a total of 22 weeks. In the statin treatment group (n=25), the ApoE-deficient mice were treated with pravastatin (80 mg/kg/day) dissolved in water by daily oral inoculation from 25 to 30 weeks of age. For the control group (n=25), the ApoE-deficient mice were orally inoculated with water only for the same period of time. The aortic gene expression affected by pravastatin was identified using oligonucleotide microarray technology with Agilent gene chips.
RESULTS: The total cholesterol and atherosclerotic lesion/total aortic area were significantly lower in the pravastatin treatment group. Microarray analysis of the expression of 20,281 murine genes in the aortas between the two groups indicated that 94 genes were significantly regulated. Thirty genes were up-regulated and 64 genes were down-regulated. The most up-regulated genes were troponin T3, actin alpha1, tubulin alpha1, regulator of G-protein signaling 5 (Rgs5), stathmin-like 2 and myosin light chain kinase. Most of them are related with cytoskeleton organization, while Rgs5 is a G-protein signal transduction molecule. The most down-regulated genes were adenosine deaminase, atrial natriuretic peptide, troponin T2, FXYD domain-containing ion transport regulator 3, and glutathione S-transferase alpha4.
CONCLUSIONS: The beneficial effect of the 6-week statin treatment in ApoE-deficient mice is largely dependent on its influence on the cytoskeleton organization. Our study results might provide insight into the clinical benefits of chronic statin treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16678288     DOI: 10.1016/j.ijcard.2006.01.009

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  The role of the blood transcriptome in innate inflammation and stroke.

Authors:  Jane E Freedman; Olga Vitseva; Kahraman Tanriverdi
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

2.  Association Study Between Polymorphic Loci in Cholesterol Metabolism Pathway and Gallstone in the Tibetan Population.

Authors:  Lifeng Ma; Hui Chen; Zhiying Zhang; Lijun Liu; Yiduo Zhao; Yansong Li; Zhipeng Zhao; Haitao Chen; Longli Kang
Journal:  Front Genet       Date:  2022-05-16       Impact factor: 4.772

3.  Statins cause profound effects on gene expression in human cancer cells in vitro: the role of membrane microdomains.

Authors:  David John Garnett; Trevor James Greenhough
Journal:  Gene Expr       Date:  2012

4.  PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis.

Authors:  Grant D Barish; Annette R Atkins; Michael Downes; Peter Olson; Ling-Wa Chong; Mike Nelson; Yuhua Zou; Hoosang Hwang; Heonjoong Kang; Linda Curtiss; Ronald M Evans; Chih-Hao Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-12       Impact factor: 11.205

Review 5.  Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering.

Authors:  Marios Margaritis; Keith M Channon; Charalambos Antoniades
Journal:  Antioxid Redox Signal       Date:  2014-01-03       Impact factor: 8.401

6.  Diabetogenic effect of pravastatin is associated with insulin resistance and myotoxicity in hypercholesterolemic mice.

Authors:  Estela Lorza-Gil; Marta García-Arevalo; Bianca Cristine Favero; Maria Cristina C Gomes-Marcondes; Helena C F Oliveira
Journal:  J Transl Med       Date:  2019-08-27       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.